-
1
Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial
Published 2023-08-01“…The completed CAPRISA 012A and 012B phase 1 trials provided critical data for the CAPRISA 012C trial, which is divided into parts A and B. …”
Get full text
Article -
2
Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial
Published 2020-11-01“…This bNAb was subsequently structurally engineered and the clinical variant is now referred to as CAP256V2LS.Methods and analysis CAPRISA 012B is the second of three trials in the CAPRISA 012 bNAb trial programme. …”
Get full text
Article -
3
-
4
NK cell phenotypic profile during active TB in people living with HIV-evolution during TB treatment and implications for bacterial clearance and disease severity
Published 2023-07-01“…Here, we utilized peripheral blood specimens from the Improving Retreatment Success CAPRISA 011 study to characterize NK cell phenotypes during active TB in individuals with or without HIV co-infection. …”
Get full text
Article -
5
-
6
Higher plasma interleukin − 6 levels are associated with lung cavitation in drug-resistant tuberculosis
Published 2023-08-01“…Methods Plasma samples were obtained from 128 participants from the CAPRISA 020 Individualized M(X)drug-resistant TB Treatment Strategy Study (InDEX) prior to treatment initiation. …”
Get full text
Article -
7
-
8
Blood monocyte and dendritic cell profiles among people living with HIV with Mycobacterium tuberculosis co-infection
Published 2023-07-01“…Using flow cytometry, we characterized the frequencies and phenotypic differences in monocytes and dendritic cell populations using peripheral blood mononuclear cells from individuals with recurrent, active pulmonary tuberculosis with and without coexisting HIV infection (CAPRISA 011, Clinicaltrials.gov, NCT02114684, 29/01/2014) and compared them to samples from HIV positive individuals and healthy controls. …”
Get full text
Article -
9
Isoniazid resistance-conferring mutations are associated with highly variable phenotypic resistance
Published 2023-12-01Get full text
Article -
10
-
11
Clinical impact of plasma concentrations of first-line antituberculosis drugs
Published 2023-03-01Get full text
Article -
12
Biological mechanisms underpinning the development of long COVID
Published 2023-06-01Get full text
Article -
13
-
14
Long COVID: a review and proposed visualization of the complexity of long COVID
Published 2023-04-01Get full text
Article -
15
A third-line antiretroviral therapy register to track patient clinical and virological outcomes
Published 2022-08-01Get full text
Article -
16
-
17
Role of Immunity and Vaginal Microbiome in Clearance and Persistence of Human Papillomavirus Infection
Published 2022-07-01Get full text
Article -
18
-
19
Rapid Diagnosis of Drug-Resistant Tuberculosis–Opportunities and Challenges
Published 2023-12-01Get full text
Article -
20
Rapid Molecular Assays for the Diagnosis of Drug-Resistant Tuberculosis
Published 2022-08-01“…Louansha Nandlal,* Rubeshan Perumal,* Kogieleum Naidoo* Centre for the AIDS Programme of Research in South Africa (CAPRISA), South African Medical Research Council (SAMRC)-CAPRISA-TB-HIV Pathogenesis and Treatment Research Unit, University of KwaZulu-Natal Nelson R Mandela School of Medicine, Durban, South Africa*These authors contributed equally to this workCorrespondence: Rubeshan Perumal, Centre for the AIDS Programme of Research in South Africa (CAPRISA), South African Medical Research Council (SAMRC)-CAPRISA-TB-HIV Pathogenesis and Treatment Research Unit, University of KwaZulu-Natal Nelson R Mandela School of Medicine, Durban, South Africa, Email Rubeshan.Perumal@caprisa.orgAbstract: The recognition that drug-resistant tuberculosis (DR-TB) poses a major threat to global tuberculosis (TB) control efforts has catalysed the development of new and urgently needed TB diagnostics. …”
Get full text
Article